Thrombus Precursor Protein and Clinical Outcomes in Patients With Acute Coronary Syndromes

Journal of the American College of Cardiology

Volumn 51, Issue 25, 2008, Pages 2422-2429

  Mega, Jessica L ^a   Morrow, David A ^a   de Lemos, James A ^b   Mohanavelu, Satishkumar ^a   Cannon, Christopher P ^a   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; FIBRIN; POLYMER; PROTEIN PRECURSOR; THROMBUS PRECURSOR PROTEIN; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; FIBRIN FORMATION; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS;

ACUTE CORONARY SYNDROME; ADULT; BIOLOGICAL MARKERS; BLOOD COAGULATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY THROMBOSIS; FEMALE; FIBRIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; ODDS RATIO; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; TROPONIN I;

EID: 44949209266     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.01.069     Document Type: Article

References (36)

1. Morrow D.A., Cannon C.P., Jesse R.L., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115 (2007) e356-e375
2. Morrow D.A., and Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 108 (2003) 250-252
3. van der Putten R.F., Glatz J.F., and Hermens W.T. Plasma markers of activated hemostasis in the early diagnosis of acute coronary syndromes. Clin Chim Acta 371 (2006) 37-54
4. Fuster V., and Verstraete M. Thrombosis in Cardiovascular Disorders (1992), W. B. Saunders Company, Philadelphia, PA 9-11
5. Loscalzo J., and Schafer A. Thrombosis and Hemorrhage (1994), Blackwell Scientific Publications, Boston, MA 10726
6. Cannon C.P., McCabe C.H., Wilcox R.G., et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 102 (2000) 149-156
7. Gargan P.E. Immunoassay and kit for in vitro detection of soluble desAABB fibrin polymers. United States Patent 5453359 (1995) 1-39
8. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
9. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (2003) 1264-1272
10. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 31 (1998) 1460-1465
11. Nelson W. Theory and applications of hazard plotting for censored failure data. Technometrics 14 (1972) 945-965
12. Aalen O.O. Nonparametric inference for a family of counting processes. Ann Stat 701 (1978) 26
13. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 50 (2007) e1-e157
14. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., van de Loo J.C., and European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332 (1995) 635-641
15. Benderly M., Graff E., Reicher-Reiss H., Behar S., Brunner D., Goldbourt U., and The Bezafibrate Infarction Prevention (BIP) Study Group. Fibrinogen is a predictor of mortality in coronary heart disease patients. Arterioscler Thromb Vasc Biol 16 (1996) 351-356
16. Thompson S.G., Fechtrup C., Squire E., et al. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol 16 (1996) 357-362
17. Ernst E. Fibrinogen as a cardiovascular risk factor-interrelationship with infections and inflammation. Eur Heart J 14 Suppl K (1993) 82-87
18. Bolibar I., Kienast J., Thompson S.G., Matthias R., Niessner H., Fechtrup C., and ECAT Angina Pectoris Study Group. Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease. Am Heart J 125 (1993) 1601-1605
19. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
20. Moss A.J., Goldstein R.E., Marder V.J., et al. Thrombogenic factors and recurrent coronary events. Circulation 99 (1999) 2517-2522
21. Menown I.B., Mathew T.P., Gracey H.M., et al. Prediction of Recurrent Events by D-Dimer and Inflammatory Markers in Patients with Normal Cardiac Troponin I (PREDICT) Study. Am Heart J 145 (2003) 986-992
22. Nossel H.L., Yudelman I., Canfield R.E., et al. Measurement of fibrinopeptide A in human blood. J Clin Invest 54 (1974) 43-53
23. Alkjaersig N., and Fletcher A.P. Catabolism and excretion of fibrinopeptide-A. Blood 60 (1982) 148-156
24. Hermens W.T., Pelsers M.M., Mullers-Boumans M.L., de Zwaan C., and Glatz J.F. Combined use of markers of muscle necrosis and fibrinogen conversion in the early differentiation of myocardial infarction and unstable angina. Clin Chem 44 (1998) 890-892
25. Nieuwenhuizen W. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review. Blood Coagul Fibrinolysis 4 (1993) 93-96
26. Carville D.G., Dimitrijevic N., Walsh M., et al. Thrombus precursor protein (TpP): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin Chem 42 (1996) 1537-1541
27. Derhaschnig U., Laggner A.N., Roggla M., et al. Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. Clin Chem 48 (2002) 1924-1930
28. Oldgren J., Linder R., Grip L., Siegbahn A., and Wallentin L. Coagulation activity and clinical outcome in unstable coronary artery disease. Arterioscler Thromb Vasc Biol 21 (2001) 1059-1064
29. Lee L.V., Ewald G.A., McKenzie C.R., and Eisenberg P.R. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb Vasc Biol 17 (1997) 628-633
30. Ottani F., and Galvani M. Prognostic role of hemostatic markers in acute coronary syndromes patients. Clin Chim Acta 311 (2001) 33-39
31. Hetland O., Knudsen A., Dickstein K., and Nilsen D.W. Characteristics and prognostic impact of plasma fibrin monomer (soluble fibrin) in patients with coronary artery disease. Blood Coagul Fibrinolysis 13 (2002) 301-308
32. Laurino J.P., Pelletier T.E., Eadry R., and Kounavis A. Thrombus precursor protein and the measurement of thrombosis in patients with acute chest pain syndrome. Ann Clin Lab Sci 27 (1997) 338-345
33. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 108 (2003) 1772-1778
34. Cohen M., Bhatt D.L., Alexander J.H., et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 115 (2007) 2642-2651
35. Laux V., Perzborn E., Kubitza D., and Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor xa inhibitor. Semin Thromb Hemost 33 (2007) 515-523
36. Turpie A.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 27 (2007) 1238-1247